<DOC>
	<DOCNO>NCT01777217</DOCNO>
	<brief_summary>The purpose study determine Vesicare ( Solifenacin succinate ) effective treat over-active bladder symptom radiation therapy prostate .</brief_summary>
	<brief_title>VESIcare For Improving OAB Symptoms Patients Undergoing IGRT Prostate</brief_title>
	<detailed_description>This randomize double blind placebo control flexible dose 12 week study . Following screening , subject receive first dose study medication follow completion AUASS questionnaire first day radiation treatment ( baseline ) continue twelve week . Subjects start 5 mg study medication . The AUASS complete baseline , week 4 , 8 12 . A 16 week visit conduct phone interview .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>1 . Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve write Informed Consent privacy language per HIPAA Authorization USA test site obtain subject legally authorize representative prior initiation study ( include withdrawal prohibit medication , applicable ) 2 . Subject must ambulatory male least 18 year age . 3 . Subject diagnosed prostate carcinoma elect undergo external beam radiation therapy . 4 . Subject willing complete American Urology Association Symptom Score ( AUASS ) Questionnaire . 1 . Subject undergone prostatectomy 2 . Subject exhibit symptom urinary tract infection . 3 . Subject exhibit severe neurologic damage undergone prostatectomy . 4 . Subject diagnose OAB treat medication alleviation OAB symptom within 12 month prior Screening Visit . 5 . Subject evidence uncontrolled narrow angle glaucoma , urinary gastric retention , neurogenic bladder ; prostatitis , persistent UTI . 6 . Subject exhibit hypersensitivity Solifenacin succinate , ingredient , anticholinergic agent . 7 . Subject undergone treatment investigational drug within 30 day prior screen procedure . 8 . Subject exhibited history diagnose gastrointestinal obstructive disease . 9 . Subjects comorbid low urinary tract symptom ( LUTS ) . 10 . Subjects exhibit clinically significant bladder outflow obstruction ( BOO ) . 11 . In opinion Study Investigator , patient exhibit prior screen Baseline visit , clinically significant disease medical condition would exclude subject participate study . 12 . Subjects receive prior pelvic radiation . 13 . Subjects history severe hepatic impairment . 14 . Subjects history Congenital Acquired QT prolongation .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Urination Disorder</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Prostate Cancer Radiation</keyword>
	<keyword>Vesicare</keyword>
</DOC>